Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06864988 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 100 → 95 locationsv6
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 103 to 100v5 Show 1 more changeShow less
    • Study sites: 103 to 100
  3. Enrollment target: 400 to 480 Study sites: 99 to 103v4 Show 1 more changeShow less
    • Study sites: 99 to 103
  4. Study sites: 95 to 99 Eligibility criteria expanded, about 21 wordsv3 Show 1 more changeShow less
    • Eligibility criteria expanded, about 21 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 96 to 95v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Trial Details
NCT Number NCT06864988
Lead Sponsor 4D Molecular Therapeutics
Conditions Macular Neovascularization Secondary to Age-Related Macular Degeneration
Enrollment 480 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov